Unstable diabetes in a patient receiving anti-TNF-α for rheumatoid arthritis [2]

Rheumatology

Volumn 46, Issue 1, 2007, Pages 178-179

  Boulton, John G ^a   Bourne, J T ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b CHESTERFIELD ROYAL HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOSE; INFLIXIMAB; INSULIN; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; CASE REPORT; CORRELATION ANALYSIS; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HOSPITAL ADMISSION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIA; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845586799     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel322     Document Type: Letter

References (10)

1. Kalden JR. Emerging role of anti-tumour necrosis factor therapy in rheumatic diseases. Arthritis Res 2002;4(Supp 2):S34-40.
2. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumour necrosis factor alpha: Direct role in obesity linked insulin resistance. Science 1993;259:87-91.
3. Hotamisligil GS. Increased adipose tissue expression of tumour necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
4. Kern PA, Ranganathan S. Adipose tissue necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J of Physiol Endocrinol Metab 2001;280:E745-51.
5. Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 2003;66:1440.
6. Alberti KGMM. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabetic Medi 2004;15:539-53.
7. Makimattila S, Virkamaki A, Malmstrom R, Utriainen T, Yki-Jarvinen H. Insulin resistance in type I diabetes mellitus: A major role for reduced glucose extraction. J Clin Endocrinol Metab 1996;81:707-12.
8. Ofei F, Hurel S, Newkirk J. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycaemic control in patients with NIDDM. Diabetes 1996;45:881-5.
9. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumour necrosis factor receptor: Fc fusion protein in obese insulin resistant patients. J Clin Endocr Metab 2000;85:1316-9.
10. Yazdani-Biuki B, Stezl H. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF alpha antibody infliximab. Eur J Clin Invest 2004;34:641-2.